Stocks Abbott Laboratories

More

  • Abbott's Covering The Bases Thursday, 14 Aug 2008 | 1:28 PM ET

    The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Stents, Drugs or Both: Debate May Get New Life Wednesday, 13 Aug 2008 | 6:08 PM ET

    A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.

  • Week Ahead: Volatile Stocks, Oil Watch, Fed on Hold Monday, 4 Aug 2008 | 11:12 AM ET
    FED_RESERVE3.jpg

    Oil prices will be the trigger for stocks in the week ahead. The Fed meets Tuesday and as usual, traders will watch for nuances in the Fed's post-meeting statement.

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Web Extra: Here Comes The Sun Wednesday, 16 Jul 2008 | 6:54 PM ET
    webxtra_thumb.jpg

    In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.

  • Abbott Profit Tops Forecast; Drugs, Devices Shine Wednesday, 16 Jul 2008 | 11:17 AM ET
    abbott_labs_earnngs.jpg

    Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.

  • Inflation, Stock Prices Worry Market Wednesday, 16 Jul 2008 | 9:06 AM ET

    Which is the Street more worried about--declining stock prices, particularly for financials, or inflation? It's both, and this morning's action illustrates that concern. It's been a roller coaster of a morning, up on Wells Fargo, down on consumer inflation higher than expected.

  • Market Insider: Wednesday Look Ahead Tuesday, 15 Jul 2008 | 8:05 PM ET

    Oil's move could be a key trend in Wednesday's markets, as traders watch more Fed testimony, a bunch of earnings reports and another helping of inflation data.

  • To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now. 

  • Stock Picks: Medical Device Makers Monday, 14 Jul 2008 | 11:09 AM ET

    At a time of market uncertainty, what can an investor count on?  Knee replacements, for one thing.  Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.

  • Market Insider: Wednesday Look Ahead Tuesday, 8 Jul 2008 | 8:02 PM ET

    The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.

  • Oil Drops, Stocks Pop Tuesday, 8 Jul 2008 | 5:51 PM ET
    graphic_word_ofthe_street.jpg

    The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"

  • Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.

  • Abbott wins OK for drug-coated heart stent Wednesday, 2 Jul 2008 | 4:34 PM ET

    Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.

  • Abbott, Boston Scientific Stents & Stuff Tuesday, 1 Jul 2008 | 10:33 AM ET
    Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • The Week in Review: Bears on the Prowl Saturday, 28 Jun 2008 | 3:01 PM ET
    picks_pans_badge.jpg

    By anyone's reckoning, it was a rough week.  Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged.  But all week, even through the worst of the market's sell-offs, CNBC guests offered

  • Beaten Down? Snap Them Up, Picker Says Friday, 27 Jun 2008 | 1:28 PM ET

    Where some stock-market investors see losses, Eric Schoenstein sees discounts.  His four-star Jensen Portfolio is up an average of 4.7 percent per year over the last three years, and he's singled out some stocks he finds exceptionally promising and very reasonably priced.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • Pops & Drops: Abbott Labs, Starbucks... Friday, 16 May 2008 | 6:47 PM ET

    Following are the week’s biggest winners and losers. Find out why shares of Abbott Labs and Starbucks popped while CBS and Dillard's dropped.

  • J&J Stent Ad Under Fire in Medical Journal Wednesday, 14 May 2008 | 5:01 PM ET
    Johnson & Johnson

    Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.